FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Tim Eisen

Research Profile

Disorders

Concepts & Ideas

Procedures

Genes & Molecular Sequences

Single Nucleotide Polymorphism

Physiology

Genetic Predisposition to Disease

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Yufei Wang; Peter Broderick; Athena Matakidou; Tim Eisen; richard Houlston
Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers.
Tim Eisen; Uwe Trefzer; Anne Hamilton; Peter Hersey; Michael Millward; Robert D Knight; Jarl U Jungnelius; John Glaspy
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Peter Broderick; Yufei Wang; Jayaram Vijayakrishnan; Athena Matakidou; Margaret R Spitz; Tim Eisen; Christopher I Amos; richard Houlston
Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Tim Eisen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Yufei Wang; Peter Broderick; Athena Matakidou; Tim Eisen; richard Houlston
Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers.
Carcinogenesis 2010;31(2):234-8.
2010: Tim Eisen; Uwe Trefzer; Anne Hamilton; Peter Hersey; Michael Millward; Robert D Knight; Jarl U Jungnelius; John Glaspy
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Cancer 2010;116(1):146-54.
2009: Peter Broderick; Yufei Wang; Jayaram Vijayakrishnan; Athena Matakidou; Margaret R Spitz; Tim Eisen; Christopher I Amos; richard Houlston
Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study.
Cancer research 2009;69(16):6633-41.
2009: Maria Chiara Di Bernardo; Athena Matakidou; Tim Eisen; richard Houlston
Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
Lung cancer (Amsterdam, Netherlands) 2009;65(2):237-41.
2009: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Staehler; Sylvie Negrier; Christine Chevreau; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Sibyl Anderson; Gloria Hofilena; Minghua Shan; Carol Pena; Chetan Lathia; Ronald M Bukowski
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(20):3312-8.
2009: Mark Tuthill; Martin Gore; Patrick Maxwell; Linda Pyle; Ravi Barod; Shern Chew; Terry Cook; Tim Eisen
A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib.
BMJ case reports 2009;2009():.
2008: Tim Eisen; Athena Matakidou; richard Houlston
Identification of low penetrance alleles for lung cancer: the GEnetic Lung CAncer Predisposition Study (GELCAPS).
BMC cancer 2008;8():244.
2007: Michelle L Harrison; Eva Obermueller; Nick R Maisey; Susan Hoare; Kim Edmonds; Ningfeng F Li; David Chao; Kate Hall; Chooi Lee; Eleni Timotheadou; Kellie Charles; Roger Ahern; D Mike King; Tim Eisen; Robert Corringham; Mark DeWitte; Frances R Balkwill; Martin Gore
Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4542-9.
2007: Athena Matakidou; Rachid El Galta; Emily L Webb; Matthew Rudd; Helen Bridle; Tim Eisen; richard Houlston
Genetic variation in the DNA repair genes is predictive of outcome in lung cancer.
Human molecular genetics 2007;16(19):2333-40.
2007: Athena Matakidou; Rachid El Galta; Emily L Webb; Matthew Rudd; Helen Bridle; Tim Eisen; richard Houlston
Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patients.
Lung cancer (Amsterdam, Netherlands) 2007;57(2):207-12.
2007: Athena Matakidou; Rachid El Galta; Matthew Rudd; Emily L Webb; Helen Bridle; Tim Eisen; richard Houlston
Prognostic significance of folate metabolism polymorphisms for lung cancer.
British journal of cancer 2007;97(2):247-52.
2007: Athena Matakidou; Rachid El Galta; Matthew Rudd; Emily L Webb; Helen Bridle; Tim Eisen; richard Houlston
Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis.
British journal of cancer 2007;96(12):1904-7.
2007: James M G Larkin; S A Hughes; D A Beirne; Poulam M Patel; I M Gibbens; S C Bate; K Thomas; Tim Eisen; Martin E Gore
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
British journal of cancer 2007;96(1):44-8.
2007: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Sorafenib in advanced clear-cell renal-cell carcinoma.
The New England journal of medicine 2007;356(2):125-34.
2007: Usman Khalid; A Spiro; Christine Baldwin; B Sharma; Camilla McGough; Andrew R Norman; Tim Eisen; M E R O'Brien; D Cunningham; H J N Andreyev
Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2007;15(1):39-46.
2006: Marina Parton; Martin Gore; Tim Eisen
Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(35):5584-92.
2006: James M G Larkin; Tim Eisen
Kinase inhibitors in the treatment of renal cell carcinoma.
Critical reviews in oncology/hematology 2006;60(3):216-26.
2006: Tim Eisen; T Ahmad; K T Flaherty; Martin Gore; S Kaye; R Marais; I Gibbens; S Hackett; M James; L M Schuchter; Katherine L Nathanson; Chenghua Xia; Ronit Simantov; Brian Schwartz; M Poulin-Costello; P J O'Dwyer; Mark J Ratain
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
British journal of cancer 2006;95(5):581-6.
2006: Timothy A Yap; Tim Eisen
Adjuvant therapy of renal cell carcinoma.
Clinical genitourinary cancer 2006;5(2):120-30.
2006: Athena Matakidou; Tim Eisen; Christina Fleischmann; Helen Bridle; richard Houlston
Evaluation of xeroderma pigmentosum XPA, XPC, XPD, XPF, XPB, XPG and DDB2 genes in familial early-onset lung cancer predisposition.
International journal of cancer. Journal international du cancer 2006;119(4):964-7.
2006: Matthew Rudd; Emily L Webb; Athena Matakidou; Gabrielle Sellick; Richard D Williams; Helen Bridle; Tim Eisen; richard Houlston
Variants in the GH-IGF axis confer susceptibility to lung cancer.
Genome research 2006;16(6):693-701.
2006: Mark J Ratain; Tim Eisen; Walter M Stadler; Keith T Flaherty; Stan B Kaye; Gary Rosner; Martin Gore; Apurva A Desai; Amita Patnaik; Henry Q Xiong; Eric K Rowinsky; James L Abbruzzese; Chenghua Xia; Ronit Simantov; Brian Schwartz; Peter J O'Dwyer
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2505-12.
2006: P Nathan; D Chao; C Brock; P Savage; M Harries; M Gore; Tim Eisen
The place of VEGF inhibition in the current management of renal cell carcinoma.
British journal of cancer 2006;94(9):1217-20.
2006: James M G Larkin; Penny J Norsworthy; Roger P A'Hern; Tim Eisen; Martin E Gore; Colin D Porter
Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanoma.
Melanoma research 2006;16(2):157-63.
2006: James Mg Larkin; Tim Eisen
Renal cell carcinoma and the use of sorafenib.
Therapeutics and clinical risk management 2006;2(1):87-98.
2006: Chooi P Lee; Poulam M Patel; Peter J Selby; Barry W Hancock; Ian Mak; Lynda Pyle; Maggie G James; Debbie A Beirne; Sarah Steeds; Roger A'Hern; Martin E Gore; Tim Eisen
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):898-903.
2005: Athena Matakidou; Tim Eisen; richard Houlston
Systematic review of the relationship between family history and lung cancer risk.
British journal of cancer 2005;93(7):825-33.
2005: Athena Matakidou; Tim Eisen; Helen Bridle; Mary O'Brien; Rosalind Mutch; richard Houlston
Case-control study of familial lung cancer risks in UK women.
International journal of cancer. Journal international du cancer 2005;116(3):445-50.
2004: Riyaz N H Shah; Tanya Ahmad; Tim Eisen
Treatment of recurrent or metastatic renal cell carcinoma.
Expert review of anticancer therapy 2004;4(6):1069-80.
2004: Justin S Waters; C Moss; Lynda Pyle; M James; S Hackett; R A'hern; M Gore; Tim Eisen
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
British journal of cancer 2004;91(10):1763-8.
2004: Eleni Andreopoulou; Paul J Ross; M E R O'Brien; Hugo Ford; Kathy Priest; Tim Eisen; Alison Norton; Sue Ashley; Ian E Smith
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(9):1406-12.
2004: S L Morris; S H Low; Roger P A'Hern; Tim Eisen; Martin E Gore; christopher nutting; K J Harrington
A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma.
British journal of cancer 2004;91(5):829-33.
2004: Paul J Ross; Sue Ashley; Alison Norton; Kathy Priest; Justin S Waters; Tim Eisen; Ian E Smith; M E R O'Brien
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
British journal of cancer 2004;90(10):1905-11.
2004: Nada Al-Tassan; Tim Eisen; Julie Maynard; Helen Bridle; Bindiya Shah; Christina Fleischmann; Julian R Sampson; Jeremy P Cheadle; richard Houlston
Inherited variants in MYH are unlikely to contribute to the risk of lung carcinoma.
Human genetics 2004;114(2):207-10.
2003: Athena Matakidou; Tim Eisen; richard Houlston
TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis.
Mutagenesis 2003;18(4):377-85.
2002: RH de Boer; Tim Eisen; P A Ellis; Stephen R D Johnston; Geraldine Walsh; Sue Ashley; Ian E Smith
A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(6):889-94.
2001: J Stebbing; C Benson; Tim Eisen; Lynda Pyle; K Smalley; Helen Bridle; Ian Mak; F Sapunar; Roger Ahern; Martin E Gore
The treatment of advanced renal cell cancer with high-dose oral thalidomide.
British journal of cancer 2001;85(7):953-8.
2000: Tim Eisen
Thalidomide in solid tumors: the London experience.
Oncology (Williston Park, N.Y.) 2000;14(12 Suppl 13):17-20.
2000: M J Allen; M Vaughan; A Webb; S Johnston; P Savage; Tim Eisen; S Bate; J Moore; Roger Ahern; Martin E Gore
Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
British journal of cancer 2000;83(8):980-5.
2000: MM Vaughan; J Moore; PG Riches; Stephen R D Johnston; Roger P A'Hern; ME Hill; Tim Eisen; M J Ayliffe; J M Thomas; Martin E Gore
GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(9):1183-9.
2000: K Smalley; Tim Eisen
The involvement of p38 mitogen-activated protein kinase in the alpha-melanocyte stimulating hormone (alpha-MSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells.
FEBS letters 2000;476(3):198-202.
2000: Tim Eisen; C Boshoff; Ian Mak; F Sapunar; MM Vaughan; Lynda Pyle; Stephen R D Johnston; Roger Ahern; Ian E Smith; Martin E Gore
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
British journal of cancer 2000;82(4):812-7.
1998: Tim Eisen; Ian E Smith; S Johnston; P A Ellis; JA Prendiville; Matt Seymour; Geraldine Walsh; Sue Ashley
Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1350-7.